Journal article
A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: The Anglo–Danish–Dutch Study of Intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe) study
RK Simmons, K Borch-Johnsen, T Lauritzen, GEHM Rutten, A Sandbæk, M Van Den Donk, JA Black, L Tao, ECF Wilson, MJ Davies, K Khunti, SJ Sharp, NJ Wareham, SJ Griffin
Health Technology Assessment | NIHR JOURNALS LIBRARY | Published : 2016
DOI: 10.3310/hta20640
Abstract
Background: Intensive treatment (IT) of cardiovascular risk factors can halve mortality among people with established type 2 diabetes but the effects of treatment earlier in the disease trajectory are uncertain. Objective: To quantify the cost-effectiveness of intensive multifactorial treatment of screen-detected diabetes. Design: Pragmatic, multicentre, cluster-randomised, parallel-group trial. Setting: Three hundred and forty-three general practices in Denmark, the Netherlands, and Cambridge and Leicester, UK. Participants: Individuals aged 40–69 years with screen-detected diabetes. Interventions: Screening plus routine care (RC) according to national guidelines or IT comprising screening ..
View full abstractGrants
Awarded by Research and Development
Funding Acknowledgements
The ADDITION-Netherlands study was supported by unrestricted grants from Novo Nordisk, GlaxoSmithKline and Merck and by the Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht. The ADDITION-Leicester was supported by the Department of Health and ad hoc Support Sciences, the NIHR Health Technology Assessment programme (grant reference number 08/116/300), NHS R&D support funding [including the Primary Care Research and Diabetes Research Networks and the Leicestershire, Northampton and Rutland (LNR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC)] and the NIHR. MJD and KK receive support from the Department of Health NIHR Programme Grants for Applied Research funding scheme (grant reference number RP-PG-0606-1272).